China’s Bio-product Market Reach 135 Billion RMB in 2016
According to latest data from Medicine Economic Reporter, China’s Bio-medicine market scale have reached 135 Billion Yuan in 2016, 9.2% of the total medicine market, rising by 11.5% yoy. Consumption sum of top 100 bio-medicine in public hospitals in major cities has expanded to 13.61 billion Yuan at an increase of 13.78% yoy.
Source: Medicine Economic Reporter
Currently antibiotic antibody drugs draw most attention in macromolecular drug market. Top 4 antibody drugs are Trastuzumab, Bevacizumab, Nimotuzumab and Rituximab. According to CFDA, Consumption sum of Top 4 antibiotic antibody drugs in top 100 public hospitals of major cities has reached 1.85 billion Yuan with a growth of 21.38% yoy, of which market size has expended over 4.4 billion Yuan, conquering nearly half of antibody drug market in China.
Rituximab has become the leader in antibody drugs. Market scale of Rituximab have continuously grown to 1.67 Yuan in 2016. of Rituximab in public hospitals of major cities is 734 million Yuan 22.94% yoy growth.
Trastuzumab has better performance in anti-breast-cancer care. Market size of Trastuzumab has reached 1.19 billion Yuan, and its consumption sum in public hospitals of major cities is 607 million Yuan with 14.2% yoy expansion.
Bevacizumab is the first anti-tumor-angiogenesis drug. Its market size grows rapidly with expanded indications, already reaching 1.2 billion Yuan. Consumption sum in public hospitals of major cities already over 360 million Yuan, rising by 37.43% yoy.
Nimotuzumab is the first domestic anticancer antibody drug in China, of which market size has increased above 2 billion Yuan with consumption sum of 145 million in public hospitals of major cities, expanded by 11.96%.
Generally, the share of bio-medicine in Chinese market is rising year by year, with share of chemical medicine going down. Antibiotic antibody drugs have been proven of great potential in clinic. And currently Chinese pharmaceutical companies are still far behind international companies as 3 of top 4 antibody drugs are imported from abroad.